Phase 11 study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation |
| |
| Authors: | David A Decker Muhyi Al Sarraf Cynthia Kresge Donald Austin Harvey I. Wilner |
| |
| Affiliation: | (1) Division of Medical Oncology, Department of Medicine, Wayne State University, Detroit, Michigan, USA;(2) Department of Neurosurgery, Wayne State University, Detroit, Michigan, USA;(3) Department of Radiology, Wayne State University, Detroit, Michigan, USA;(4) Harper-Grace Hospitals, 514 Hudson, 3990 John R, 48201 Detroit, MI, USA |
| |
| Abstract: | Seventeen patients with malignant gliomas recurrent after chemotherapy and/ or radiation failure were treated with aziridinylbenzoquinone (AZQ) at a dose of 20-15 mg/M2 weekly for four weeks followed by a two week rest. Regression of disease was observed in four patients, 4/17 (24%) for 35, 15+,40+, and 10 weeks. Toxicity was limited to moderate reversible myelosuppression. AZQ in this dose and schedule has limited but definite activity in patients with malignant gliomas progressive after primary radiation therapy failure. |
| |
| Keywords: | malignant gliomas chemotherapy |
| 本文献已被 SpringerLink 等数据库收录！ |
|
